Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week?

Capricor Therapeutics Inc (CAPR) is around the top of the Biotechnology industry according to InvestorsObserver. CAPR received an overall rating of 66, which means that it scores higher than 66 percent of all stocks. Capricor Therapeutics Inc also achieved a score of 77 in the Biotechnology industry, putting it above 77 percent of Biotechnology stocks. Biotechnology is ranked 15 out of the 148 industries.

CAPR has an Overall Score of 66. Find out what this means to you and get the rest of the rankings on CAPR!

See Full CAPR Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Capricor Therapeutics Inc Stock Today?

Capricor Therapeutics Inc (CAPR) stock is higher by 13% while the S&P 500 has fallen -0.28% as of 2:34 PM on Friday, Mar 8. CAPR is higher by $0.66 from the previous closing price of $5.04 on volume of 406,722 shares. Over the past year the S&P 500 has risen 31.26% while CAPR is higher by 22.32%. CAPR lost -$1.15 per share the over the last 12 months. Click Here to get the full Stock Report for Capricor Therapeutics Inc stock.